QVA149
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Introduction: The combination of two bronchodilators with different mechanisms of action to treat patients with chronic…
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological…
OBJECTIVES
QVA149 is a dual bronchodilator, containing a fixed-dose combination of the long-acting β2-agonist indacaterol and…
Introduction Exacerbations are the most frequent cause of hospitalisation and death among patients with COPD. Combinations of…
Introduction
QVA149 is a once-daily dual bronchodilator combining the long-acting β2-agonist indacaterol and long-acting…
Introduction
Current COPD treatment guidelines recommend LABA/ICS for severe COPD patients (pts) with a history of…
Introduction
Patients (pts) with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such…
Introduction QVA149 is a novel inhaled once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2…
Abstract Objective: To report performance characteristics and robustness of the Breezhaler device, a new capsule based dry powder…